Nika Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020
Selling, General & Admin	0.08	0.1	0.06	0.18	0.01	Upgrade
Research & Development	-	-	-	3	-	Upgrade
Operating Expenses	0.08	0.1	0.06	3.18	0.01	Upgrade
Operating Income	-0.08	-0.1	-0.06	-3.18	-0.01	Upgrade
Pretax Income	-0.08	-0.1	-0.06	-3.18	-0.01	Upgrade
Net Income	-0.08	-0.1	-0.06	-3.18	-0.01	Upgrade
Net Income to Common	-0.08	-0.1	-0.06	-3.18	-0.01	Upgrade
Shares Outstanding (Basic)	1,048	1,022	876	724	396	Upgrade
Shares Outstanding (Diluted)	1,048	1,022	876	724	396	Upgrade
Shares Change (YoY)	2.53%	16.62%	21.02%	82.78%	-	Upgrade
EPS (Basic)	-0.00	-0.00	-0.00	-0.00	-0.00	Upgrade
EPS (Diluted)	-0.00	-0.00	-0.00	-0.00	-0.00	Upgrade
EBIT	-0.08	-0.1	-0.06	-3.18	-0.01	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.